189 related articles for article (PubMed ID: 9492389)
1. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
2. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.
Iribarne C; Berthou F; Baird S; Dréano Y; Picart D; Bail JP; Beaune P; Ménez JF
Chem Res Toxicol; 1996 Mar; 9(2):365-73. PubMed ID: 8839037
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
7. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone.
Moody DE; Alburges ME; Parker RJ; Collins JM; Strong JM
Drug Metab Dispos; 1997 Dec; 25(12):1347-53. PubMed ID: 9394023
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
12. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
14. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
16. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
Holmstock N; Annaert P; Augustijns P
Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Wolf T; Findhammer S; Nolte B; Helm EB; Brodt HR
Eur J Med Res; 2003 Jan; 8(1):17-24. PubMed ID: 12578750
[TBL] [Abstract][Full Text] [Related]
18. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.
Iribarne C; Picart D; Dréano Y; Berthou F
Fundam Clin Pharmacol; 1998; 12(2):194-9. PubMed ID: 9565774
[TBL] [Abstract][Full Text] [Related]
19. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
20. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Duan SX; Fogelman SM; Daily JP; Harmatz JS; Shader RI
J Clin Pharmacol; 1998 Feb; 38(2):106-11. PubMed ID: 9549640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
